Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.